A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

Completed · Early Phase 1 · Has a placebo group

Conditions studied: Tinea Pedis

In brief

To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.

Key facts

Study ID

NCT04883593

Run by

Sun Pharmaceutical Industries, Inc.

People needed

160

Starts

2020-09-03

Expected to finish

2021-02-20

Last updated by the study team

2021-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or non pregnant female aged ≥ 18 years
• Subjects must have provided IRB approved written informed consent
• Subjects must have clinical diagnosis of interdigital tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin).

You may not qualify if…

• Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
• Subjects with a history of hypersensitivity or allergy to any of the study medication ingredients and its excipients.
• Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.

Where it is running

• Catawba Research, LLC — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.